Dougal McClean

4.4k total citations · 2 hit papers
51 papers, 3.0k citations indexed

About

Dougal McClean is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Dougal McClean has authored 51 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Surgery, 25 papers in Cardiology and Cardiovascular Medicine and 18 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Dougal McClean's work include Coronary Interventions and Diagnostics (45 papers), Cardiac Imaging and Diagnostics (18 papers) and Cardiac Valve Diseases and Treatments (14 papers). Dougal McClean is often cited by papers focused on Coronary Interventions and Diagnostics (45 papers), Cardiac Imaging and Diagnostics (18 papers) and Cardiac Valve Diseases and Treatments (14 papers). Dougal McClean collaborates with scholars based in New Zealand, Netherlands and Australia. Dougal McClean's co-authors include Patrick W. Serruys, Yoshinobu Onuma, Dariusz Dudek, Bernard Chevalier, Stephan Windecker, Jacques Koolen, John A. Ormiston, Héctor M. García‐García, Pieter C. Smits and Bernard De Bruyne and has published in prestigious journals such as The Lancet, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Dougal McClean

47 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Evaluation of the Second Generation of a Bioresorbable Everolimus-Eluting Vascular Scaffold for the Treatment of De Novo Coronary Artery Stenosis

2011 414 citations Patrick W. Serruys, Yoshinobu Onuma et al. Journal of the American College of Cardiology profile →
Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial

2016 350 citations Patrick W. Serruys, Bernard Chevalier et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dougal McClean New Zealand	24	2.7k	1.6k	1.1k	719	199	51	3.0k
Francesco Liïstro Italy	28	2.4k 0.9×	1.4k 0.9×	1.3k 1.1×	797 1.1×	141 0.7×	74	3.0k
Stephen N. Oesterle United States	30	1.7k 0.7×	1.5k 0.9×	428 0.4×	741 1.0×	148 0.7×	81	2.7k
Lynn Bailey United States	17	1.1k 0.4×	784 0.5×	346 0.3×	237 0.3×	35 0.2×	40	1.5k
Neal E. Fearnot United States	18	921 0.3×	1.4k 0.9×	552 0.5×	291 0.4×	57 0.3×	51	2.1k
H. Singer Germany	28	534 0.2×	652 0.4×	560 0.5×	112 0.2×	108 0.5×	108	2.3k
Faisal Sharif Ireland	23	755 0.3×	645 0.4×	284 0.3×	341 0.5×	15 0.1×	109	1.5k
Erhan Tenekecioğlu Netherlands	22	1.1k 0.4×	913 0.6×	477 0.4×	509 0.7×	20 0.1×	137	1.8k
Л. С. Барбараш Russia	17	592 0.2×	542 0.3×	316 0.3×	121 0.2×	106 0.5×	265	1.3k
Wei-Jen Shih United States	19	273 0.1×	209 0.1×	355 0.3×	391 0.5×	66 0.3×	171	1.4k
Ömer Göktekín Türkiye	18	880 0.3×	1.2k 0.8×	754 0.7×	337 0.5×	20 0.1×	92	2.1k

Countries citing papers authored by Dougal McClean

Since Specialization

Citations

This map shows the geographic impact of Dougal McClean's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dougal McClean with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dougal McClean more than expected).

Fields of papers citing papers by Dougal McClean

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dougal McClean. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dougal McClean. The network helps show where Dougal McClean may publish in the future.

Co-authorship network of co-authors of Dougal McClean

This figure shows the co-authorship network connecting the top 25 collaborators of Dougal McClean. A scholar is included among the top collaborators of Dougal McClean based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dougal McClean. Dougal McClean is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Scott, Douglas, Madhav Menon, Dougal McClean, et al.. (2024). Percutaneous Coronary Intervention Using the DynamX Sirolimus‐Eluting Bioadaptor: 12‐Month Clinical and Imaging Outcomes. Journal of Interventional Cardiology. 2024(1).

Collet, Carlos, Bernard Chevalier, Ángel Cequier, et al.. (2017). Diagnostic Accuracy of Coronary CT Angiography for the Evaluation of Bioresorbable Vascular Scaffolds. JACC. Cardiovascular imaging. 11(5). 722–732. 12 indexed citations

Serruys, Patrick W., John Ormiston, Robert‐Jan van Geuns, et al.. (2016). A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis. Journal of the American College of Cardiology. 67(7). 766–776. 119 indexed citations

Serruys, Patrick W., Bernard Chevalier, Yohei Sotomi, et al.. (2016). Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. The Lancet. 388(10059). 2479–2491. 350 indexed citations breakdown →

Meredith, Ian T., Warwick M. Jaffe, Seif El‐Jack, et al.. (2015). NINE-MONTH PRIMARY ENDPOINT RESULTS OF THE EVOLVE II QCA STUDY: A PROSPECTIVE, MULTICENTER TRIAL ASSESSING CLINICAL, ANGIOGRAPHIC, AND INTRAVASCULAR ULTRASOUND OUTCOMES WITH THE NOVEL PLATINUM-CHROMIUM ABLUMINALLY-COATED BIOABSORBABLE POLYMER SYNERGY EVEROLIMUS-ELUTING STENT IN DE NOVO CORONARY STENOSES. Journal of the American College of Cardiology. 65(10). A1789–A1789. 1 indexed citations

Bourantas, Christos V., Patrick W. Serruys, Shimpei Nakatani, et al.. (2015). Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data. EuroIntervention. 11(8). 746–756. 36 indexed citations

Onuma, Yoshinobu, Patrick W. Serruys, Takashi Muramatsu, et al.. (2014). Incidence and Imaging Outcomes of Acute Scaffold Disruption and Late Structural Discontinuity After Implantation of the Absorb Everolimus-Eluting Fully Bioresorbable Vascular Scaffold. JACC: Cardiovascular Interventions. 7(12). 1400–1411. 87 indexed citations

Gómez‐Lara, Josep, Roberto Diletti, Salvatore Brugaletta, et al.. (2012). Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study. EuroIntervention. 8(2). 214–224. 35 indexed citations

Brugaletta, Salvatore, Josep Gómez‐Lara, Nico Bruining, et al.. (2012). Head to head comparison of optical coherence tomography, intravascular ultrasound echogenicity and virtual histology for the detection of changes in polymeric struts over time: insights from the ABSORB trial. EuroIntervention. 8(3). 352–358. 3 indexed citations

10.

Grube, Eberhard, Franz–Josef Neumann, Stefan Verheye, et al.. (2011). Very Long Term Clinical Outcomes of Patients with Coronary Bifurcation Lesions Treated with the Biolimus A9 Coated Dedicated Axxess Stent: Results from the Prospective, Multicenter AXXESS Plus Trial (Final Report of the Study). Journal of the American College of Cardiology. 58(20). 1 indexed citations

11.

Gómez‐Lara, Josep, Salvatore Brugaletta, Vasim Farooq, et al.. (2011). Head-to-Head Comparison of the Neointimal Response Between Metallic and Bioresorbable Everolimus-Eluting Scaffolds Using Optical Coherence Tomography. JACC: Cardiovascular Interventions. 4(12). 1271–1280. 51 indexed citations

12.

Gómez‐Lara, Josep, Maria Radu, Salvatore Brugaletta, et al.. (2011). Serial Analysis of the Malapposed and Uncovered Struts of the New Generation of Everolimus-Eluting Bioresorbable Scaffold With Optical Coherence Tomography. JACC: Cardiovascular Interventions. 4(9). 992–1001. 65 indexed citations

13.

Brugaletta, Salvatore, Josep Gómez‐Lara, Héctor M. García‐García, et al.. (2011). Analysis of 1 year virtual histology changes in coronary plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. International journal of cardiac imaging. 28(6). 1307–1314. 10 indexed citations

14.

Onuma, Yoshinobu, Patrick W. Serruys, Bernard De Bruyne, et al.. (2011). Comparison of in vivo acute stent recoil between the bioresorbable everolimus‐eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus‐eluting stent. Catheterization and Cardiovascular Interventions. 78(1). 3–12. 93 indexed citations

15.

Meredith, Ian T., Stephen G. Worthley, Robert Whitbourn, et al.. (2010). Long-term clinical outcomes with the next-generation Resolute Stent System: a report of the two-year follow-up from the RESOLUTE clinical trial. EuroIntervention. 5(6). 692–697. 30 indexed citations

16.

Meredith, Ian T., Stephen G. Worthley, Robert Whitbourn, et al.. (2009). Clinical and Angiographic Results With the Next-Generation Resolute Stent System. JACC: Cardiovascular Interventions. 2(10). 977–985. 96 indexed citations

17.

Ormiston, John A., Ehtisham Mahmud, Mark Turco, et al.. (2008). Direct Stenting With the TAXUS Liberté Drug-Eluting Stent. JACC: Cardiovascular Interventions. 1(2). 150–160. 23 indexed citations

18.

Grube, Eberhard, Lutz Buellesfeld, Franz‐Josef Neumann, et al.. (2007). Six-Month Clinical and Angiographic Results of a Dedicated Drug-Eluting Stent for the Treatment of Coronary Bifurcation Narrowings. The American Journal of Cardiology. 99(12). 1691–1697. 59 indexed citations

19.

Serruys, Patrick W., Georgios Sianos, Alexandre Abizaid, et al.. (2005). The Effect of Variable Dose and Release Kinetics on Neointimal Hyperplasia Using a Novel Paclitaxel-Eluting Stent Platform. Journal of the American College of Cardiology. 46(2). 253–260. 132 indexed citations

20.

McClean, Dougal, Kaname Takizawa, Michael C. Fishbein, et al.. (2003). Elution of everolimus and sirolimus from a biodegradable polymer coated stent inhibits neointimal hyperplasia without inflammation or toxicity. Journal of the American College of Cardiology. 41(6). 6–6. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact